- Home
- SNAL vs GUTS Comparison
SNAL vs GUTS Comparison
Compare SNAL & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- GUTS
- Stock Information
- Founded
- SNAL 2000
- GUTS 2010
- Country
- SNAL United States
- GUTS United States
- Employees
- SNAL 97
- GUTS N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- GUTS
- Sector
- SNAL Technology
- GUTS
- Exchange
- SNAL Nasdaq
- GUTS NYSE
- Market Cap
- SNAL 92.8M
- GUTS 110.1M
- IPO Year
- SNAL 2022
- GUTS 2024
- Fundamental
- Price
- SNAL $2.51
- GUTS $1.82
- Analyst Decision
- SNAL
- GUTS Buy
- Analyst Count
- SNAL 0
- GUTS 2
- Target Price
- SNAL N/A
- GUTS $18.00
- AVG Volume (30 Days)
- SNAL 102.2K
- GUTS 373.0K
- Earning Date
- SNAL 11-13-2024
- GUTS 02-02-2025
- Dividend Yield
- SNAL N/A
- GUTS N/A
- EPS Growth
- SNAL N/A
- GUTS N/A
- EPS
- SNAL 0.08
- GUTS N/A
- Revenue
- SNAL $86,822,973.00
- GUTS $97,000.00
- Revenue This Year
- SNAL $39.43
- GUTS N/A
- Revenue Next Year
- SNAL $26.12
- GUTS N/A
- P/E Ratio
- SNAL $33.21
- GUTS N/A
- Revenue Growth
- SNAL 82.23
- GUTS N/A
- 52 Week Low
- SNAL $0.52
- GUTS $1.74
- 52 Week High
- SNAL $2.65
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- SNAL 69.71
- GUTS 41.31
- Support Level
- SNAL $1.75
- GUTS $1.77
- Resistance Level
- SNAL $2.04
- GUTS $2.10
- Average True Range (ATR)
- SNAL 0.24
- GUTS 0.16
- MACD
- SNAL 0.03
- GUTS -0.01
- Stochastic Oscillator
- SNAL 84.45
- GUTS 9.18
About SNAL Snail Inc.
Snail Inc is a global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.